European Commission approves second indication of Sarclisa® (isatuximab) for relapsed multiple myeloma
The Pharma Data
APRIL 28, 2021
Approval based on Phase 3 IKEMA study demonstrating Sarclisa added to standard of care carfilzomib and dexamethasone reduced risk of disease progression or death by 47% in patients who had relapsed after one to three prior therapies. The carfilzomib and dexamethasone combination represents an important standard of care in Europe.
40 
Let's personalize your content